Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PIP5K1A | Q99755 | 4/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.48 |
| ▸ | CETP | P11597 | 3/20 | 0.45 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Totarol SCHEMBL13423504 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTUSP2TP53MEN1 | |
| Totarol SCHEMBL285501 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTUSP2TP53MEN1 | |
| Totarol SCHEMBL30105648 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTUSP2TP53MEN1 | |
| Totarol SCHEMBL16238019 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTUSP2TP53MEN1 | |
| Totarol SCHEMBL31121504 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTUSP2TP53MEN1 | |
| 19-Hydroxytotarol SCHEMBL12998342 | 0.85 | CYP3A4 (1.00) | CYP3A4MAPTUSP2TP53MEN1 | |
| 19-Hydroxytotarol SCHEMBL13423507 | 0.85 | CYP3A4 (1.00) | CYP3A4MAPTUSP2TP53MEN1 | |
| Totarol SCHEMBL31287563 | 0.85 | CYP3A4 (0.74) | CYP3A4MAPTUSP2TP53MEN1 | |
| SCHEMBL5522477 | 0.84 | CYP3A4 (0.78) | CYP3A4MAPTUSP2TP53MEN1 | |
| SCHEMBL20970940 | 0.84 | USP2 (0.82) | CYP3A4MAPTUSP2TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2166040-A1 | Novel lipophilic fluorescent dyes and a process for their production | RADIANT COLOR N.V. (BE) | 2010-03-24 | — | — | EP | claimed |
| JP-1311019-A | — | — | None | — | — | JP | disclosed |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | disclosed |
| US-12458653-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12427176-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2025-09-30 | — | — | US | disclosed |
| CN-120131508-A | Composition with effects of controlling oil, removing acnes and repairing barrier and application thereof | 北京植物医生生物科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-12303488-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-05-20 | — | — | US | disclosed |
| CN-119488441-A | Method for relieving eye visual fatigue and liquid composition for eye use | 北京济亦生物医药有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2021025584-A2 | FULLERENE-CONTAINING AGENTS FOR COMPREHENSIVE CARE OF THE ORAL CAVITY | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТИ "СПЛАТ ГЛОБАЛ" | 2021-02-11 | — | — | WO | disclosed |
| US-20160157483-A1 | COMPOSITION FOR THE CLEANING AND PROTECTION OF TECHNICAL SURFACES | AIMECS GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| EP-2143703-B1 | Method for the preparation of (+)-totarol | COGNIS IP MAN GMBH (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100112100-A1 | COMPOSITIONS COMPRISING A C-GLYCOSIDE COMPOUND | L'OREAL (FR) | 2010-05-06 | — | — | US | disclosed |
| EP-2166040-A1 | Novel lipophilic fluorescent dyes and a process for their production | RADIANT COLOR N.V. (BE) | 2010-03-24 | — | — | EP | disclosed |
| EP-2143703-A1 | Method for the preperation of (+)-totarol | Cognis IP Management GmbH (DE) | 2010-01-13 | — | — | EP | disclosed |
| WO-2007038875-A1 | CCR5 RECEPTOR ANTAGONIST MOLECULES | AVANCE PHARMA INC. (CA) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007038875-A1 | CCR5 RECEPTOR ANTAGONIST MOLECULES | AVANCE PHARMA INC. (CA) | 2007-04-12 | — | — | WO | disclosed |
| JP-H01311019-A | ANTIBACTERIAL AGENT, EXTERNAL PREPARATION OF SKIN AND COMPOSITION FOR ORAL CAVITY USING THE SAME AGENT | SHISEIDO CO LTD | 1989-12-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, NEFM | CYP3A4 4882/4885MAPT 35/4885USP2 1129/4885 |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR1, CNR2, OPRM1 | CYP3A4 1136/4885MAPT 719/4885USP2 4554/4885 |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | CYP3A4 1979/4885MAPT 37/4885USP2 4459/4885 |
| US-20100112100-A1 | COMPOSITIONS COMPRISING A C-GLYCOSIDE COMPOUND | UGCG, GANC, CUTA | CYP3A4 4378/4885MAPT 2919/4885USP2 2787/4885 |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | CYP3A4 4670/4885MAPT 411/4885USP2 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.